Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


XBiotech Inc. (XBIT) announced the FDA issued an emergency use authorization for COVID-19 Convalescent Plasma as a COVID-19 treatment, opening the door for the company's antibody screening technology used to identify Convalescent Plasma. Under Collaboration, BioBridge Global will be using XBiotech's COVID-19 antibody test to identify the convalescent blood products.


RTTNews | Aug 24, 2020 09:05AM EDT

09:04 Monday, August 24, 2020 (RTTNews.com) - XBiotech Inc. (XBIT) announced the FDA issued an emergency use authorization for COVID-19 Convalescent Plasma as a COVID-19 treatment, opening the door for the company's antibody screening technology used to identify Convalescent Plasma. Under Collaboration, BioBridge Global will be using XBiotech's COVID-19 antibody test to identify the convalescent blood products.

XBiotech said the Agency's preliminary findings show that the use of convalescent plasma (or blood with natural anti-COVD-19 antibodies from patients that recovered from the infection) is safe and effective in treating COVID-19.

Shares of XBiotech were up 14% in pre-market trade on Monday.

Read the original article on RTTNews ( https://www.rttnews.com/3123426/xbiotech-shares-surge-on-fda-emergency-use-authorization-of-convalescent-plasma.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC